| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AG-014699 | GDSC1000 | pan-cancer | AAC | -0.14 | 5e-05 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.32 | 0.0009 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.003 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.004 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.21 | 0.005 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.092 | 0.006 |